Glysantis™ is a biomedical company active in preclinical research and development of novel nano-medicines. Through our proprietary NanoGlys™ platform, Glysantis™ is developing therapies for a wide range of clinical indications.
Monodisperse carbohydrate nano-particles are at the core of our technology. Easily modified they can be designed to be novel active ingredients for targeted drug delivery, imaging or diagnostics. They can improve stability, solubility and bioavailability of existing drugs. Their structure and non-toxicity makes it possible to overcome the biological barriers that limit the effectiveness of many therapies today.
We focus on leveraging our NanoGlys™ technology platform across clinical indications and industries. Areas of interest are targeted drug delivery, cancer treatment, antiviral agents, antibiotics and imaging agents.
In addition to our own laboratory facilities our resources include commercial partnerships and collaborations with national and international research facilities.